The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was reported that the Trump administration had dropped its plans to impose tariffs on ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

It's the Trump administration's latest move to rein in high prescription drug costs in the U.S., and could be a blow to pharmaceutical companies.

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug ...

The US Food and Drug Administration (FDA) has announced major steps to make it faster and less costly to develop biosimilar ...

The "The FDA (Food and Drug Administration) Drug Approval Process Training Course (Feb 23rd - Feb 24th, 2026)" training has been added to ResearchAndMarkets.com's offering.

Indian pharmaceutical companies are gaining ground in the Chinese market, winning bids to supply bulk generic drugs, including Dapagliflozin for diabetes treatment. Hetero Labs Limited, Cipla Ltd, ...

The U.S. Food and Drug Administration (FDA) has announced major steps to make it faster and less costly to develop biosimilar medicines, lower-cost "generic" alternatives to biologic drugs used to ...

In a groundbreaking move, the Trump administration is tackling the pressing issue of high healthcare costs by accelerating the development of affordable generic medications. In a press conference ...

There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...